In a significant move to enhance access to essential medications, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) of China have jointly released the updated "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024 Edition)." This new list, officially published on November 27, 2024, reflects ongoing efforts to improve the healthcare benefits available to insured individuals across the country.

Among the key updates, MEBO has been reapproved for inclusion in the 2024 Drug List, under the category of Chinese patent medicines, with the registration number 890. This marks a continued recognition of the product’s significant role in the treatment of burn injuries.

MEBO is a groundbreaking therapeutic solution designed for burn recovery and wound regeneration. Recognized for its exceptional innovation and proven clinical efficacy, the ointment has earned numerous international patents. It is now used in over 100,000 medical institutions across China, benefiting millions of patients annually. The product has demonstrated not only impressive healing rates but also plays an essential role in reducing disability and mortality rates among burn victims. Its inclusion in the national drug list underscores the value of traditional Chinese medicine (TCM) in modern healthcare, showcasing its critical contribution to improving patient outcomes.

About MEBO

Founded in 1987 by Professor Rongxiang Xu, a distinguished Chinese life scientist, MEBO Group is a multinational headquartered in both China and the USA. It integrates research, development, and sales across the pharmaceuticals, medical devices, health foods, and cosmetics sectors.

At its core, MEBO focuses on regenerative life sciences, innovating with over 100 patents and more than ten joint research bases to enhance and enable the body's own regenerative abilities.

As a leader in regenerative life science, MEBO's extensive research facilities and products impact over 100 countries globally, pioneering new frontiers in the regenerative life world.